Villepinte (France), May 6, 2019 – Guerbet, a global specialist in contrast agents and solutions for medical imaging, has announced the launch of its website for interventional radiologists, specializing particularly in the fields of oncology and vascular embolization: www.guerbet-interventional.com.

The aim of this new site is to keep practicing professionals informed and up to speed by delivering rich scientific content, including videos, scientific conference agendas, clinical and epidemiological data, diagrams, clinical cases and scientific images. It will group information on the latest practices in interventional imaging and its associated conditions, on mini-invasive procedures, and on the interventional imaging solutions proposed by Guerbet with their mechanisms of action.

This new specialized site focuses specifically on three main indications particularly well-suited to interventional imaging: treatment of primary liver cancer (hepatocellular carcinoma) with conventional transarterial chemoembolization (cTACE); treatment of vascular abnormalities by embolization; and embolization therapy and visualization of lymphatic effusions.

Guerbet has been developing its activities in the field of interventional imaging over recent years, marketing not only innovative mix and injection system for standardizing cTACE, but also microcatheters to complete the range. The company’s recent creation of a franchise dedicated to this specialty is a further reflection of its growing commitment in this sector. Guerbet has also just launched a website specializing in women’s health, with focus on infertility & breast cancer managements: www.guerbet-womenhealthcare.com.

Press release

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.